<DOC>
	<DOC>NCT02238223</DOC>
	<brief_summary>Study to investigate the safety and efficacy information of Alesion速 Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching</brief_summary>
	<brief_title>Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion速 Tablet</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>All the patients who: haven't treatment experience of epinastine product; have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma Alesion速 Tablet is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion速 Tablet in package insert. However, it is unknown whether a patient is hypersensitive to the ingredients of the product in almost cases. And this survey is drug utilization study to observe actual use in any patients. Therefore exclusion criteria is not set in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>